RxDoctor Payments Data

Darya Heim, MD

Family Medicine · Ephrata, PANPI 1346697398

Payments from drug & device makers

$1,006in general payments, 2019–2025

Across 12 payments — averaging $83.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$176
  • AstraZeneca$125
  • GSK$125
  • Gilead$124
  • Boston Scientific$120
  • Merck$111
  • plus $225 from 4 others

What the payments were for

  • Food & beverage$1,006100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,006 in reported general payments places this provider in the 65th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$25,153
Medicare patients
98
Services billed
352

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin28$32,740
EliquisApixaban38$28,680
JanuviaSitagliptin Phosphate14$11,636
MyrbetriqMirabegron12$8,529
Breo ElliptaFluticasone/Vilanterol15$5,879
BrilintaTicagrelor11$4,311
Albuterol Sulfate HfaAlbuterol Sulfate42$1,607
Atorvastatin Calcium125$1,062
Pregabalin18$915
Metoprolol Succinate70$914
Levothyroxine Sodium104$889
Omeprazole86$881
Gabapentin62$805
Famotidine61$748
Escitalopram Oxalate61$741

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$111$11,63614 claims
GSKBreo Ellipta$125$5,87915 claims
AstraZenecaBrilinta$125$4,31111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Ephrata

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →